JPMorgan Initiates Overweight on Tango Therapeutics with $46 Target as Pancreatic Cancer Data Impresses
Strong 92% ORR and 90% 6-month PFS in pancreatic cancer combo data fuel bullish sentiment.
Strong 92% ORR and 90% 6-month PFS in pancreatic cancer combo data fuel bullish sentiment.
The new treatment, given with fulvestrant with or without palbociclib, nearly quadrupled progression-free survival versus standard therapy.
Despite missing the primary endpoint, the drug advances to Phase 3 in 2027 with a favorable safety profile.
Health Canada has approved Mounjaro for children with type 2 diabetes.
Eli Lilly participates in Absci’s $100M equity offering to fund ABS-201, a novel prolactin receptor antibody showing strong safety in Phase 1 for pattern hair loss and endometriosis.
The deals cover key gene therapy platforms and the Fabry disease program in a court-supervised auction.